Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026

2025-12-11 16:11:03 ET

The last time I spoke about Abivax SA ( ABVX ) it was with respect to a Seeking Alpha article entitled " Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalys t". At that time, I reported that the company had released positive results from both of its phase 3 ABTECT 8-week induction trials using its first-in-class miR-124 enhancer obefazimod [ABX464] to treat patients with moderate-to-severe active Ulcerative Colitis [UC]. Both of these trials were ABTECT-1 [Study 105] and ABTECT-2 [Study 106], and individually patients who took 50 mg of this drug were able to achieve a placebo-adjusted remission rate of 19.3% and 13.4%, respectively. At that time, I rated the company a "Strong Buy" rating and based on its recent progress, I'm going to maintain this rating. Especially, even though the stock price has traded higher by more than 90% since the last time I wrote about it. But if it has made all of these gains, then why do I believe that it is important to keep this rating? and why investors should keep an eye on this name. The reason why is because the company released two additional data items from the phase 3 ABTECT 8-week induction trials....

Read the full article on Seeking Alpha

For further details see: